Screening Children for Inherited High Cholesterol
Tests a blood sample to screen children aged 2 to 18 for familial hypercholesterolemia.
Key facts
- Who runs it
- Centre Hospitalier Universitaire, Amiens
- Where
- Amiens, FranceSee the site
- Trial code
- Registry title
- Screening for Familial Hypercholesterolemia in Children
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 2 Jan 2025
- Expected to end
- Feb 2027
- Type of study
- Interventional
- Treatments tested
- blood sample
- Record updated
- 12 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 2 to 18 to be screened for familial hypercholesterolemia with a fasting blood sample.
- Age
- 2 to 18 years
- Sex
- Boys and girls can both join.
Main reasons for not taking part
- Known familial hypercholesterolemia
- Diabetes less than one month old
- Profound hypothyroidism
- Acute nephrotic syndrome
- Cancer under treatment
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age between 2 and 18 years
- Minimum 8-hour fasting
- Parents and children with signed informed consent
Who cannot take part
- Diabetes less than one month old
- Acute nephrotic syndrome
- cancer under treatment
- Known familial hypercholesterolemia
- Profound hypothyroidism
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 18 years old?
Where in France
- CHRU AmiensAmiens, FranceContact: Gwendoline Buissart, MDTaking people
About the trial
What the trial wants to find out
Familial hypercholesterolemia is the most common treatable genetic disorder for which a simple, effective treatment is available, with few side effects.
Read full original descriptionShow less
It leads to a significant increase in LDL levels, generally in excess of 1.9g/l, including in children. It is much higher than the values usually found in secondary or polygenic hypercholesterolemia. This condition multiplies the cardiovascular risk in adulthood by a factor of 13, and is responsible for 6,500 early cardiovascular events per year. In the absence of treatment, the state of the arteries of patients with familial hypercholesterolemia, at the age of 40, would be equivalent to that of 80-year-olds.
Currently, the prevalence is estimated at 1 in 300 people in France. However, this prevalence is largely underestimated, as targeted screening is rarely carried out, and it is estimated that only 10% of sufferers are diagnosed in France, and only 5% of affected children are known and treated.
Today, according to the French health authority, the indications for screening children are: a history of an early vascular event in one of the two parents, or familial hypercholesterolemia in a first-degree relative.
However, the World Health Organization and numerous studies recommend extending screening to the general population. Screening all children and teenagers could make it possible to introduce healthy dietary habits at an early stage, to better adapt the choice of contraception in young women, to treat before the first symptoms appear and thus reduce mortality in adulthood by up to 48%, and to screen relatives who have not yet had a cardiovascular event.
In Slovenia, 90% of children have had a lipid panel since 1994, significantly reducing mortality. In the United Kingdom, the lipid check-up, offered as part of a compulsory visit at the age of two, is being rolled out: 90% of families naturally take it up on the recommendation of their doctors.
The treatment of hypercholesterolemia is simple, and relies first and foremost on hygienic dietary rules and treatments such as statins and Liptruzet (a combination of atorvastatin and ezetimibe), treatments that are easily accessible, effective, with few side effects and low cost.
Treatments tested
- blood sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Screening for Familial Hypercholesterolemia in Children
- Plain-language title
- Screening Children for Inherited High CholesterolGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06555120, who can take part
- Record updated
- 12 February 2026